Analyst Price Targets — ELUT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 21, 2024 8:43 am | Frank Takkinen | Loop Capital Markets | $10.00 | $3.50 | StreetInsider | Aziyo Biologics Inc. (ELUT) PT Raised to $10 at Lake Street Capital Markets |
| May 10, 2024 8:11 am | Ross Osborn | Cantor Fitzgerald | $5.00 | $3.29 | TheFly | Elutia price target lowered to $5 from $6 at Cantor Fitzgerald |
| November 16, 2022 9:52 am | — | Truist Financial | $10.00 | $7.64 | Benzinga | Truist Securities Maintains Buy on Aziyo Biologics, Raises Price Target to $10 |
| November 14, 2022 9:11 pm | Matt O'Brien | Piper Sandler | $10.50 | $8.20 | TheFly | Aziyo Biologics price target raised to $10.50 from $9 at Piper Sandler |
Latest News for ELUT
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Dr. Michelle Williams, Chief Scientific Officer, will present and host one-on-one meetings with investors at the Planet MicroCap Showcase 2026 at the Bellagio in Las Vegas, Nevada on June…
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on May 13, 2026 to one new employee as an inducement award under the Elutia Inc. 2026 Inducement Award Plan (the “Plan”).
Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript
NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scale Chief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant unmet need and market opportunity Strong balance sheet with $36.5 million in cash and escrowed proceeds from the BioEnvelope…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ELUT.
U.S. House Trading
No House trades found for ELUT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.